However, the WJOG-8715 L trial compared osimertinib plus bevacizumab vs. osimertinib alone, and the combination treatment did not lead to prolonger PFS in patients with advanced lung adenocarcinoma with EGFR T790 M mutation (HR = 1.44, 95% CI: 0.83–2.52; P=0.20). Here, EGFR is linked to lung adenocarcinoma.